Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid

Madhav A. Namjoshi, Richard Risser, Lizheng Shi, Mauricio Tohen, Alan Breier

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder. Methods: Patients with bipolar I disorder, were randomized to receive either olanzapine (5-20 mg) added to mood stabilizer therapy (n=224), or placebo added to mood stabilizer therapy (n=112) for 6 weeks. Changes in clinical outcomes over 6 weeks were measured by the Young Mania Rating Scale (Y-MRS) and the Hamilton Rating Scale for Depression (HAM-D). Quality of life was measured by the Lehman Brief Quality of Life Interview (QLI). Results: Patients treated with olanzapine added to mood stabilizers, experienced significantly greater mean clinical improvements from baseline on both the Y-MRS and the HAM-D compared to those treated with placebo added to mood stabilizers. Over 6 weeks, patients treated with olanzapine added to mood stabilizers had significantly greater mean improvements from baseline on five of the nine subjective scales on the QLI, compared to patients treated with placebo added to mood stabilizers. Changes in scores on the subjective scales of the QLI were more strongly correlated to changes in depressive symptomatology measured by the HAM-D, than to changes in symptoms of mania measured by the Y-MRS. Conclusion: The results of this study demonstrate that patients receiving adjunctive treatment have significantly greater improvements in both clinical and quality of life outcomes compared to monotherapy with mood stabilizers.

Original languageEnglish (US)
Pages (from-to)223-229
Number of pages7
JournalJournal of Affective Disorders
Volume81
Issue number3
DOIs
StatePublished - Sep 2004

Fingerprint

olanzapine
Valproic Acid
Bipolar Disorder
Lithium
Quality of Life
Placebos
Interviews
Therapeutics

Keywords

  • Adjunctive therapy
  • Bipolar disorder
  • Olanzapine
  • Quality of life

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. / Namjoshi, Madhav A.; Risser, Richard; Shi, Lizheng; Tohen, Mauricio; Breier, Alan.

In: Journal of Affective Disorders, Vol. 81, No. 3, 09.2004, p. 223-229.

Research output: Contribution to journalArticle

Namjoshi, Madhav A. ; Risser, Richard ; Shi, Lizheng ; Tohen, Mauricio ; Breier, Alan. / Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. In: Journal of Affective Disorders. 2004 ; Vol. 81, No. 3. pp. 223-229.
@article{91a4f7d6ef1047b2a8dd3930569fc2ae,
title = "Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid",
abstract = "Background: The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder. Methods: Patients with bipolar I disorder, were randomized to receive either olanzapine (5-20 mg) added to mood stabilizer therapy (n=224), or placebo added to mood stabilizer therapy (n=112) for 6 weeks. Changes in clinical outcomes over 6 weeks were measured by the Young Mania Rating Scale (Y-MRS) and the Hamilton Rating Scale for Depression (HAM-D). Quality of life was measured by the Lehman Brief Quality of Life Interview (QLI). Results: Patients treated with olanzapine added to mood stabilizers, experienced significantly greater mean clinical improvements from baseline on both the Y-MRS and the HAM-D compared to those treated with placebo added to mood stabilizers. Over 6 weeks, patients treated with olanzapine added to mood stabilizers had significantly greater mean improvements from baseline on five of the nine subjective scales on the QLI, compared to patients treated with placebo added to mood stabilizers. Changes in scores on the subjective scales of the QLI were more strongly correlated to changes in depressive symptomatology measured by the HAM-D, than to changes in symptoms of mania measured by the Y-MRS. Conclusion: The results of this study demonstrate that patients receiving adjunctive treatment have significantly greater improvements in both clinical and quality of life outcomes compared to monotherapy with mood stabilizers.",
keywords = "Adjunctive therapy, Bipolar disorder, Olanzapine, Quality of life",
author = "Namjoshi, {Madhav A.} and Richard Risser and Lizheng Shi and Mauricio Tohen and Alan Breier",
year = "2004",
month = "9",
doi = "10.1016/j.jad.2003.07.005",
language = "English (US)",
volume = "81",
pages = "223--229",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid

AU - Namjoshi, Madhav A.

AU - Risser, Richard

AU - Shi, Lizheng

AU - Tohen, Mauricio

AU - Breier, Alan

PY - 2004/9

Y1 - 2004/9

N2 - Background: The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder. Methods: Patients with bipolar I disorder, were randomized to receive either olanzapine (5-20 mg) added to mood stabilizer therapy (n=224), or placebo added to mood stabilizer therapy (n=112) for 6 weeks. Changes in clinical outcomes over 6 weeks were measured by the Young Mania Rating Scale (Y-MRS) and the Hamilton Rating Scale for Depression (HAM-D). Quality of life was measured by the Lehman Brief Quality of Life Interview (QLI). Results: Patients treated with olanzapine added to mood stabilizers, experienced significantly greater mean clinical improvements from baseline on both the Y-MRS and the HAM-D compared to those treated with placebo added to mood stabilizers. Over 6 weeks, patients treated with olanzapine added to mood stabilizers had significantly greater mean improvements from baseline on five of the nine subjective scales on the QLI, compared to patients treated with placebo added to mood stabilizers. Changes in scores on the subjective scales of the QLI were more strongly correlated to changes in depressive symptomatology measured by the HAM-D, than to changes in symptoms of mania measured by the Y-MRS. Conclusion: The results of this study demonstrate that patients receiving adjunctive treatment have significantly greater improvements in both clinical and quality of life outcomes compared to monotherapy with mood stabilizers.

AB - Background: The objective of this study was to determine the clinical and quality of life outcomes associated with adjunctive treatment of olanzapine added to either lithium or valproic acid/divalproex sodium in patients with bipolar disorder. Methods: Patients with bipolar I disorder, were randomized to receive either olanzapine (5-20 mg) added to mood stabilizer therapy (n=224), or placebo added to mood stabilizer therapy (n=112) for 6 weeks. Changes in clinical outcomes over 6 weeks were measured by the Young Mania Rating Scale (Y-MRS) and the Hamilton Rating Scale for Depression (HAM-D). Quality of life was measured by the Lehman Brief Quality of Life Interview (QLI). Results: Patients treated with olanzapine added to mood stabilizers, experienced significantly greater mean clinical improvements from baseline on both the Y-MRS and the HAM-D compared to those treated with placebo added to mood stabilizers. Over 6 weeks, patients treated with olanzapine added to mood stabilizers had significantly greater mean improvements from baseline on five of the nine subjective scales on the QLI, compared to patients treated with placebo added to mood stabilizers. Changes in scores on the subjective scales of the QLI were more strongly correlated to changes in depressive symptomatology measured by the HAM-D, than to changes in symptoms of mania measured by the Y-MRS. Conclusion: The results of this study demonstrate that patients receiving adjunctive treatment have significantly greater improvements in both clinical and quality of life outcomes compared to monotherapy with mood stabilizers.

KW - Adjunctive therapy

KW - Bipolar disorder

KW - Olanzapine

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=4344572522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344572522&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2003.07.005

DO - 10.1016/j.jad.2003.07.005

M3 - Article

C2 - 15337326

AN - SCOPUS:4344572522

VL - 81

SP - 223

EP - 229

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -